AnaCardio

AnaCardio is a Swedish biotech advancing a novel class of inotropic agents for heart failure, based on pioneering ghrelin pathway research from Karolinska Institutet. Its lead candidate, AC01, has demonstrated positive Phase 2a topline results in HFrEF patients, positioning it for rapid advancement into Phase 2b. The company is targeting a significant unmet need for a therapy that safely improves contractility without the dangerous side effects associated with current inotropes, across chronic, acute, and advanced heart failure settings.

Novel inotropic agents based on the ghrelin signaling pathway, designed to increase cardiomyocyte contractility and cardiac output without causing adverse tachycardia, arrhythmia, ischemia, or hypotension.

Competes against standard chronic HF therapies (e.g., SGLT2 inhibitors, ARNIs) that do not directly improve contractility, and risky intravenous inotropes used in acute care. Faces competition from other companies developing next-generation cardiac myotropes and novel HF mechanisms.